Multifunctional nanomediator for enhanced combination cancer immunotherapy
A lipid nanoparticle modified with C7A rings and RGD ligands, encapsulating NIR-II light-activated SPN, anti-PD-L1 antibodies, and lactate oxidase nanoparticles, aims to reverse the tumor immunosuppressive microenvironment and enhance solid tumor treatment.
Overview
This innovative solution involves a multifunctional nanomediator designed to enhance cancer immunotherapy. By utilizing a lipid nanoparticle modified with C7A rings and RGD ligands, this technology encapsulates a second near-infrared (NIR-II) light-activated semiconducting polymer nanocore (SPN), anti-programmed death-ligand 1 (PD-L1) antibodies, and lactate oxidase nanoparticles. This combination aims to modulate various tumor elements to reverse the immunosuppressive microenvironment, thereby mounting an effective response against solid tumors. The technology is customizable for different cancer types and is expected to synergistically enhance conventional CAR-T therapy.
Technical specifications
- Lipid nanoparticle core: Modified with hexamethyleneimine (C7A) rings and RGD ligands for targeted delivery.
- Encapsulated components: Includes NIR-II light-activated SPN for heat generation and tumor cell death, anti-PD-L1 antibodies for immunosuppression reversal, and lactate oxidase nanoparticles for prolonged intratumoral retention and immune activation.
- Mechanism of action: Upon NIR-II activation, the nanoparticle collapses, releasing tumor antigens and promoting antitumor immune responses.
- Customization: RGD ligands and encapsulated drugs can be tailored based on specific cancer types.
Technology readiness level
Currently assessed at TRL 3, this technology has undergone initial validation in controlled environments. Future plans include intravenous injection trials in tumor-bearing mice, with detailed analysis of immune responses and tumor progression. The technology's synergistic effects with CAR-T therapy will also be evaluated in humanized mice models.
About University of Kansas
The University of Kansas is a comprehensive public research university with a multi-campus footprint centered in Lawrence and Kansas City, Kansas, combining broad academic depth with a strong applied-research culture. Industry engages through a research and technology park adjacent to campus that provides flexible lab and office space, with shared core facilities and streamlined contracting to speed sponsor work. Integration with a major academic health system and a medical center enables clinical partnerships and access to diverse patient populations. Proximity to the Kansas City metro connects partners to the region’s innovation ecosystem, while research is supported by funding from agencies such as NIH and NSF, and the technology transfer office manages IP, licensing, and startups.
delivered to your inbox.